Immunotherapies in Non-Small Cell Lung Cancer

Immunotherapy recommendations for patients with thoracic cancers are rapidly changing, and health care providers are challenged to remain aware of the most current recommendations in the NCCN Guidelines® to improve outcomes for their patients. A number of different immunotherapy regimens are now recommended in the NCCN Guidelines for certain patients with thoracic cancers. Health care providers need to be aware of new recommendations for selecting and sequencing the most appropriate systemic therapy regimens for their patients with thoracic cancers. They also need to be aware of current supportive care recommendations for managing immune mediated adverse events in patients who receive immunotherapy.

Target Audience

This educational program is designed to meet the educational needs of the interprofessional oncology care team, including physicians, nurse practitioners, nurses, pharmacists, physician assistants, and other relevant health care professionals who manage the care of patients with lung cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Identify the different immunotherapy regimens for patients with thoracic cancers.
  • Describe appropriate sequencing of therapy in patients with non small cell lung cancer who have received immunotherapy regimens.
  • Discuss the potential for immune-mediated adverse events with other health care providers and patients receiving immunotherapy.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • AstraZeneca
  • Celgene Corporation
  • Takeda Oncology

This activity is supported by a grant from Pfizer Inc.

This activity is supported by an independent educational grant from Incyte.

This project has been made possible in part by a grant from the Varian Medical Systems Educational Grant Corporate Fund, an advised fund of Silicon Valley Community Foundation.

Course summary
Available credit: 
  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation
Course opens: 
12/17/2019
Course expires: 
12/17/2020
Cost:
$0.00
Part of: 
Recorded Presentations from the NCCN 2019 Congress Series™: Lung Cancer

Julie Brahmer, MD, MSc
The Sidney Kimmel Comprehensive Cancer Center an Johns Hopkins

Michelle Turner, MS, CRNP
The Sidney Kimmel Comprehensive Cancer Center an Johns Hopkins

 

NCCN Medical Education Disclosure Policy

It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Definitions  

NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. 

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures

The faculty listed below discloses no relevant financial relationships:
Michelle Turner, MS, CRNP

The faculty listed below discloses the following relevant financial relationships:

Julie Brahmer, MD, MSc
Amgen Inc.: Consulting Fee
AstraZeneca Pharmaceuticals LP: Consulting Fee
Bristol-Myers Squibb Company: Consulting Fee; Grant/Research Support
Genentech, Inc.: Consulting Fee
Merck & Co., Inc.: Consulting Fee
Syndax: Consulting Fee

NCCN Staff Disclosures 

The NCCN Activity Planning staff listed below discloses no relevant financial relationships:

Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; 
Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Sarah Sinclair; 
Kathy Ann Smith, CHCP

The NCCN Clinical staff listed below discloses no relevant financial relationships:

Jennifer L. Burns, BS; Susan D. Darlow, PhD; Miranda Hughes, PhD; Alyse Johnson-Chilla; 
Ann Karosas, RPh, BCOP; Rashmi Kumar, PhD; Jillian Scavone, PhD (employed by NCCN until 7.26.19)

The NCCN Clinical staff listed below discloses the following relevant financial relationships:

Griselda Zuccarino-Catania, PhD
Janssen Pharmaceutica Products, LP: Spouse Salary

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.25 contact hours.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.25 contact hours (0.125 CEUs) of continuing education credit. UAN: JA4008196-0000-19-108-H01-P

Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until 12/17/2020. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need: